Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757699 | 0.90 | PTGDR2 (0.60) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1758338 | 0.90 | PTGDR2 (0.50) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1758015 | 0.87 | KDM4E (0.48) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1757823 | 0.80 | PTGDR2 (0.52) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1758032 | 0.79 | MAPT (0.52) | PTGDR2F2RL3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1757545 | 0.77 | KMT2A (0.47) | PTGDR2F2RL3KDM4EALDH1A1 | |
| SCHEMBL2206663 | 0.77 | PTGDR2 (0.47) | PTGDR2PTGS1 | |
| SCHEMBL2206918 | 0.76 | PTGDR2 (0.53) | PTGDR2PTGS1 | |
| SCHEMBL2204163 | 0.76 | PTGDR2 (0.48) | PTGDR2PTGS1 | |
| SCHEMBL1757714 | 0.76 | PTGDR2 (0.52) | PTGDR2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885F2RL3 429/4885CYP1A2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.